NCT07465913RecruitingPhase 4
Rocklatan vs Latanoprost Post-DSLT
Outcomes of Direct Selective Laser Trabeculoplasty With the Post-treatment Addition of Combination Netarsudil and Latanoprost vs Latanoprost Monotherapy
Source: ClinicalTrials.gov · Last updated 22 May 2026
Brief summary (registry, in English)
This is a randomized, double-masked, single-site, prospective, contralateral eye study designed to evaluate the outcomes of Direct Selective Laser Trabeculoplasty (DSLT) followed by the addition of combination netarsudil and latanoprost (Rocklatan) versus latanoprost monotherapy. The study will be conducted at one investigational site. The primary endpoint is the change in mean diurnal intraocular pressure (IOP) from baseline (post DSLT and post washout) at visit 3 between the two groups. Secondary endpoints include the change in mean IOP from baseline at each timepoint (8am, 12pm, 4pm) at visit 3 between groups, and the mean percentage decrease in IOP from baseline for each group. Assessments will be conducted at three key visits: Visit 1 (Screening Phase and DSLT Procedure on Day 0), Visit 2 (Baseline Visit post washout at Week 8), and Visit 3 (Follow-Up Visit 1 at Week 12). Each visit will include specific examinations and measurements such as visual field and OCT imaging, diurnal IOP measurements, and documentation of adverse events.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- First submitted
- 6 Mar 2026
- Start date
- 14 May 2026
- Primary completion date
- 6 May 2027
- Lead sponsor
- Eye Centers of Southeast Texas
- Diseases
- Glaucoma
- NCT number
- NCT07465913
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 36
- From 14 May 2026 to the primary completion date, 6 May 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Inability or medical ineligibility for washout of ocular hypotensive medications.
- Prior selective laser trabeculoplasty (SLT) within 12 months of screening.
Other illness
- Ocular hypertension only (no glaucomatous damage).
- History of glaucoma surgery (trabeculectomy, tube shunt, minimally invasive glaucoma surgery \[MIGS\] affecting outflow).
- Active ocular infection, uveitis, or severe dry eye.
- Known hypersensitivity to Rocklatan, latanoprost, or study medication components.
Other
- Narrow or closed angles with gonioscopy (Shaffer grading ≤2).
- Corneal pathology interfering with IOP measurement.
- Advanced glaucoma (threat to fixation).
- Pregnancy or lactation.
Who the study is looking for
- Adults (≥18 years) with a diagnosis of mild to moderate bilateral primary open-angle glaucoma (POAG) or open-angle glaucoma (OAG).
- On 3 topical glaucoma medications at screening, one of which must be a prostaglandin analog.
- Post-DSLT and post-washout, baseline intraocular pressure (IOP) 16-36 mmHg in both eyes.
- Best-corrected visual acuity (BCVA) ≥20/60 in both eyes.
- Ability and willingness to provide informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Eye Centers of Southeast Texas Coordinator of this site? Confirm its status | Beaumont | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.